In this handout photo released by the University of Oxford a doctor takes blood samples for use in a coronavirus vaccine trial in Oxford, England on Thursday June 25, 2020. Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. In research published Monday July 20, 2020 in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. (John Cairns, University of Oxford via AP)
By Maria Cheng
Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot.
British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are usually designed only to evaluate safety, but in this case experts were also looking to see what kind of immune response was provoked.
In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55.
“We are seeing good immune response in almost everybody,” said Dr. Adrian Hill, director of the Jenner Institute at Oxford University. “What this vaccine does particularly well is trigger both arms of the immune system,” he said.
Hill said that neutralizing antibodies are produced — molecules which are key to blocking infection. In addition, the vaccine also causes a reaction in the body's T-cells which help to fight off the coronavirus.
He said that larger trials evaluating the vaccine's effectiveness, involving about 10,000 people in the U.K. as well as participants in South Africa and Brazil are still underway. Another big trial is slated to start in the U.S. soon, aiming to enroll about 30,000 people.
How quickly scientists are able to determine the vaccine's effectiveness will depend largely on how much more transmission there is, but Hill estimated they might have sufficient data by the end of the year to decide if the vaccine should be adopted for mass vaccination campaigns.
He said the vaccine seemed to produce a comparable level of antibodies to those produced by people who recovered from a COVID-19 infection and hoped that the T-cell response would provide extra protection.
“There's increasing evidence that having a T-cell response as well as antibodies could be very important in controlling COVID-19,” Hill said. He suggested the immune response might be boosted after a second dose; their trial tested two doses administered about four weeks apart.
Hill said Oxford's vaccine is designed to reduce disease and transmission. It uses a harmless virus — a chimpanzee cold virus, engineered so it can’t spread — to carry the coronavirus’ spike protein into the body, which should trigger an immune system response.
Hill said Oxford has partnered with drugmaker AstraZeneca to produce their vaccine globally, and that the company has already committed to making 2 billion doses.
“Even 2 billion doses may not be enough,” he said, underlining the importance of having multiple shots to combat the coronavirus.
“There was a hope that if we had a vaccine quickly enough, we could put out the pandemic,” Hill said, noting the continuing surge of infections globally. “I think it's going to be very difficult to control this pandemic without a vaccine.”
Numerous countries including Germany, France, the Netherlands, Italy, U.S. and the U.K. have all signed deals to receive hundreds of millions of doses of the vaccine — which has not yet been licensed — with the first deliveries scheduled for the fall. British politicians have promised that if the shot proves effective, Britons will be the first to get it.
Last week, American researchers announced that the first COVID-19 vaccine tested there boosted people’s immune systems just as scientists had hoped and the shots will now enter the final phase of testing. That vaccine, developed by the National Institutes of Health and Moderna, produced the molecules key to blocking infection in volunteers who got it, at levels comparable to people who survived a COVID-19 infection.
About a dozen different experimental vaccines are in early stages of human testing or poised to start, mostly in China, the U.S. and Europe, with dozens more in earlier stages of development.
British officials said Monday they had also signed a deal to buy 90 million doses of experimental COVID-19 vaccines being developed by the pharmaceutical giant Pfizer and others.
In a statement, the British government said it had secured access to a vaccine candidate being developed by Pfizer and BioNTech, in addition to another experimental vaccine researched by Valneva.
Ellen Fitzsimmons-Craft, assistant professor of psychiatry at Washington University School of Medicine, joins Cheddar News to discuss how chatbots can help prevent eating disorders and the research that uncovered these findings.
Shoulder injuries are one of the most common orthopedic injuries – and they're also one of the most commonly ignored. But chimpanzees, with whom we share nearly 99% of our DNA, don’t encounter the same issues we do. So why are human shoulders such a design disaster? Well, we can trace the answer back to a very particular moment in our evolution.
As the Omicron variant continues to sweep across the country. The US Supreme Court is expected to hear arguments at the end of this week on whether or not the Biden administration can force private companies to vaccinate or test millions of their employees. In addition, the National Nurses United has spearheaded legal action to protect nurses and health care workers, patients, and the public while on the job. President of the National Nurses Union, Zenei Cortez, joined Cheddar to discuss more.
Digital medical care provider Pear Therapeutics rang the closing bell on the Nasdaq Friday and President and CEO Dr. Corey McCann, joined Cheddar to talk about how the company plans to grow the business of software-based therapeutics and how the first FDA authorized prescription digital therapeutics company will go about treating illnesses like insomnia and addiction. "These really are pieces of software. In many cases, they're apps and in the cases of our addiction products, these are based on something called cognitive behavioral therapy or CBT," he said. "These products change the patient's brain circuitry to help them be abstinent, to help them stay in treatment, and that's exactly what we see in randomized clinical trials and that's what we see in the real world." He also addressed the ongoing mental health crises brought on by the pandemic. **copy updated to remove IPO information as Pear Therapeutics went public in December**
Jake Carbone, senior data analyst at InfluenceMap joins Cheddar News to talk about a new report by The Guardian and InfluenceMap that reveals how companies are creating fossil fuel ads designed to look like Google search results.
Satellite launch service Virgin Orbit has gone public on the Nasdaq via a SPAC merger with NextGen Acquisitions with a valuation of about $3.2 billion. CEO Dan Hart joined Cheddar's "Between Bells" from in front of his LauncherOne rocket in New York City's Times Square to talk about what's next after the IPO, an upcoming "Above the Clouds" mission to deliver commercial and national security payloads, and the benefits of their rockets being launched from commercial 747 aircraft. "We can launch anywhere in the world," he said. "There are almost 80 space agencies across the world, for instance, and about 10 of them have space launch. We can give them a space flight capability overnight by taking a runway and turning it into a spaceport."
The year 2021 saw numerous natural disasters around the world, including extreme heat and wildfires, rare deep freezes, and historic flooding. This year's United Nations COP26 conference was key for getting world leaders on board with emissions reductions and other climate-focused policies as the UN Secretary-General said the agency's report on global warming is a 'code red for humanity.' In the U.S., President Joe Biden has focused most of his domestic agenda on slashing emissions and building climate-focused infrastructure. Guests from The Economist, UNC-Chapel Hill, Global Rescue, and more join Cheddar Climate's year-end special to discuss how the climate changed in 2021, and what to expect in 2022.
Digital mental health company Little Otter recently announced it closed a $22 million Series A round. Little Otter was founded in 2020 by a mother-daughter team, which based the company on the idea that a child's mental health can only be addressed by treating the whole family through technology available to everyone. Little Otter CEO and co-founder Rebecca Egger and her mother, Little Otter Chief Medical and Scientific Officer and co-founder Dr. Helen Egger joined Cheddar News' Closing Bell to discuss.
Among all the other events of the last few years, you may have missed this one: Spermageddon. This is the fun name for the idea that sperm counts among mainly ‘Western’ men are in freefall. The Spermageddon hype began with the publication of a 2017 study showing a nearly 60% drop in overall sperm counts in men living in North America, Europe, Australia, and New Zealand.
But four years later, it seems that Spermageddon has been overblown. By a lot. And all that hype has obscured the real issue behind declining male fertility.
Covid-19 has changed the way we view wellness. Jillian Hughes, communications director of Mental Health America, joins Cheddar News to discuss breaking the stigma around mental health. Justin Davis, CEO and co-founder of Spectrum Labs, weighs in on how social media impacts our wellbeing. Lastly, Precision Nutrition CEO Timothy Jones advices us on what trends to watch in 2022.
